Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF(V600E) targeted inhibition in a novel syngeneic murine glioma model

Inhibitors of BRAF(V600E) kinase are currently under investigations in preclinical and clinical studies involving BRAF(V600E) glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients tumors continue to grow despite treatment....

Descripción completa

Detalles Bibliográficos
Autores principales: Grossauer, Stefan, Koeck, Katharina, Murphy, Nicole E., Meyers, Ian D., Daynac, Mathieu, Truffaux, Nathalene, Truong, Albert Y., Nicolaides, Theodore P., McMahon, Martin, Berger, Mitchel S., Phillips, Joanna J., James, David C., Petritsch, Claudia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342782/
https://www.ncbi.nlm.nih.gov/pubmed/27713119
http://dx.doi.org/10.18632/oncotarget.12419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342782/
https://www.ncbi.nlm.nih.gov/pubmed/27713119
http://dx.doi.org/10.18632/oncotarget.12419

Ejemplares similares